On Monday, Novartis (115.76, 3.18, 2.82%) announced that its targeted radiotherapy drug, Pluvicto, has demonstrated the potential to delay the progression of a specific type of prostate cancer. This discovery brings new hope for the application of this drug technology in early – stage treatment.
Positive Results from Late – Stage Trial
The Swiss pharmaceutical company reported that findings from a late – stage trial showed that in patients with metastatic prostate cancer who were still responsive to standard hormone therapy, Pluvicto provided “clinically significant benefits” in terms of progression – free survival. Additionally, there was a positive trend observed in overall survival.
Current and Potential Treatment Scenarios
Novartis added that nearly all of these patients would eventually develop a form of cancer that no longer responds to hormone therapy, and Pluvicto has already been approved for use in treating this more advanced condition. The company stated, “These data indicate that (Pluvicto) can be used in the early stages of the disease,” highlighting that this could potentially address a significant unmet medical need.
Future Plans for Data Disclosure and Regulatory Approval
Novartis only provided a summary of the trial results, stating that detailed information would be revealed at a medical conference. The company also suggested that it might seek broader regulatory approval for wider use of the drug in the second half of this year.
The Technology Behind Pluvicto
Pluvicto belongs to a class of drugs that combine radioactive particles, which are capable of killing cells, with molecules that attach to tumors. Novartis holds a leading position in the development of this type of drug technology.
Strong Revenue Growth of Pluvicto
The drug has also been performing well commercially. In the first quarter, its revenue increased by 20%, reaching $371 million.
Related topics:
